triple glp 1 gip glucagon receptor agonist Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research Triple Agonists for Diabetes: Why
Description
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
doi: 10.1016/j.biopha.2020.110218 188 Simental-MendaLESnchez-GarcaALinden-TorresESimental-MendaM
doi: 10.1523/JNEUROSCI.2212-10.2011
doi: 10.1111/bpa.12402 [DOI] [PMC free article] [PubMed] [Google Scholar] 69
For additional details and discussion regarding pharmacologic approaches to glycemic management, please refer to the full 2020 ADA Standards of Medical Care
92 In the subgroup analysis by preserved versus reduced LVEF, there was no difference between treatment and placebo
